CSL: R&D Investor Briefing (CSL Behring) - Jan 9, 2016 - “Manageable safety profile: Pre-medication with steroids required to prevent infusion reactions”; “PD effects confirming CD123-targeted ADCC”; “Rapid and full depletion of basophils and pDCs: Sustained depletion at CSL362 dose levels ≥ 3 mg/kg”; “Saturation of CD123 receptor on monocytes at CSL362 dose levels ≥ 3 mg/kg (trough concentration > 3μg/ml)”; “Conversion of MRD seen in a subset of pts treated with CSL362”
P1 data • Acute Myelogenous Leukemia
|